Patents by Inventor Michael E. Danielson
Michael E. Danielson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220105181Abstract: This disclosure describes, in one aspect, a method for identifying ?-glucan binding to immune cells of a subject. Generally, the method includes obtaining a blood sample from the subject, the blood sample comprising immune cells, adding soluble ?-glucan to at least a portion of the blood sample and incubating the mixture under conditions allowing the soluble ?-glucan to bind to the immune cells, and detecting soluble ?-glucan hound to the immune cells. In another aspect, this disclosure describes a method that generally includes identifying the subject as a low binder of ?-glucan, and co-administering to the subject a soluble ?-glucan and an antibody preparation capable of converting the subject from a low binder to a high binder.Type: ApplicationFiled: December 15, 2021Publication date: April 7, 2022Inventors: William J. Grossman, Mary A. Antonysamy, Richard M. Walsh, Mariana I. Nelson, Nandita Bose, Michael E. Danielson, Kyle S. Michel
-
Patent number: 11229701Abstract: This disclosure describes, in one aspect, a method for identifying ?-glucan binding to immune cells of a subject. Generally, the method includes obtaining a blood sample from the subject, the blood sample comprising immune cells, adding soluble ?-glucan to at least a portion of the blood sample and incubating the mixture under conditions allowing the soluble ?-glucan to bind to the immune cells, and detecting soluble ?-glucan bound to the immune cells. In another aspect, this disclosure describes a method that generally includes identifying the subject as a low binder of ?-glucan, and co-administering to the subject a soluble ?-glucan and an antibody preparation capable of converting the subject from a low binder to a high binder.Type: GrantFiled: March 14, 2013Date of Patent: January 25, 2022Assignee: HiberCell, Inc.Inventors: William J. Grossman, Mary A. Antonysamy, Richard M. Walsh, Mariana I. Nelson, Nandita Bose, Michael E. Danielson, Kyle S. Michel
-
Publication number: 20190064179Abstract: This disclosure provides, in one aspect, a method for analyzing a sample from a subject for a biomarker that is indicative of the subject's immune response to ?-glucan. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti-?-glucan antibody compared to a reference standard, computing a Relative Antibody Unit (RAU) value for anti-?-glucan antibody in the sample, and identifying the subject as biomarker positive if the RAU value is greater than a predetermined RAU value for the biomarker anti-?-glucan antibody.Type: ApplicationFiled: October 26, 2018Publication date: February 28, 2019Inventors: Nandita Bose, Mary A. Antonysamy, Keith B. Gorden, Richard Walsh, Michael E. Danielson, Peter Maimonis
-
Publication number: 20180369376Abstract: This disclosure describes, in one aspect, a composition that includes a ?-glucan component and an antibody component that specifically binds to the ?-glucan. In another aspect, this disclosure describes a method of increasing a subject's response to ?-glucan immunotherapy. Generally, the method includes identifying the subject as a low binder of ?-glucan and administering to the subject a composition that comprises a ?-glucan moiety conjugated to the therapeutic antibody. In some cases, the therapeutic antibody can be an anti-tumor antibody.Type: ApplicationFiled: August 31, 2018Publication date: December 27, 2018Inventors: William J. Grossman, Mary A. Antonysamy, Richard M. Walsh, Mariana I. Nelson, Nandita Bose, Michael E. Danielson, Kyle S. Michel
-
Patent number: 10114027Abstract: This disclosure provides, in one aspect, a method for analyzing a sample from a subject for a biomarker that is indicative of the subject's immune response to ?-glucan. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti-?-glucan antibody compared to a reference standard, computing a Relative Antibody Unit (RAU) value for anti-?-glucan antibody in the sample, and identifying the subject as biomarker positive if the RAU value is greater than a predetermined RAU value for the biomarker anti-?-glucan antibody.Type: GrantFiled: December 18, 2017Date of Patent: October 30, 2018Assignee: Biothera, Inc.Inventors: Nandita Bose, Mary A. Antonysamy, Keith B. Gorden, Richard Walsh, Michael E. Danielson, Peter Maimonis
-
Patent number: 10092646Abstract: This disclosure describes, in one aspect, a composition that includes a ?-glucan component and an antibody component that specifically binds to the ?-glucan. In another aspect, this disclosure describes a method of increasing a subject's response to ?-glucan immunotherapy. Generally, the method includes identifying the subject as a low binder of ?-glucan and administering to the subject a composition that comprises a ?-glucan moiety conjugated to the therapeutic antibody. In some cases, the therapeutic antibody can be an anti-tumor antibody.Type: GrantFiled: March 14, 2013Date of Patent: October 9, 2018Assignee: Biothera, Inc.Inventors: William J. Grossman, Mary A. Antonysamy, Richard M. Walsh, Mariana I. Nelson, Nandita Bose, Michael E. Danielson, Kyle S. Michel
-
Publication number: 20180256738Abstract: Described herein are beta-glucan compounds, compositions, and methods. Generally, the methods exploit the observation that beta-glucan compounds can bind to B cells. Thus, the methods generally include administering a beta-glucan compound to a subject in an amount effective for the beta-glucan compound to bind to a B cell and modulate at least one biological function of the B cell.Type: ApplicationFiled: April 5, 2018Publication date: September 13, 2018Inventors: Nandita Bose, Anissa S.H. Chan, Michael E. Danielson, Mary A. Antonysamy, John P. Vasilakos, Keith B. Gorden, Steven M. Leonardo, William J. Grossman
-
Publication number: 20180128836Abstract: This disclosure provides, in one aspect, a method for analyzing a sample from a subject for a biomarker that is indicative of the subject's immune response to ?-glucan. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti-?-glucan antibody compared to a reference standard, computing a Relative Antibody Unit (RAU) value for anti-?-glucan antibody in the sample, and identifying the subject as biomarker positive if the RAU value is greater than a predetermined RAU value for the biomarker anti-?-glucan antibody.Type: ApplicationFiled: December 18, 2017Publication date: May 10, 2018Inventors: Nandita Bose, Mary A. Antonysamy, Keith B. Gorden, Richard Walsh, Michael E. Danielson, Peter Maimonis
-
Patent number: 9943607Abstract: Described herein are beta-glucan compounds, compositions, and methods. Generally, the methods exploit the observation that beta-glucan compounds can bind to B cells. Thus, the methods generally include administering a beta-glucan compound to a subject in an amount effective for the beta-glucan compound to bind to a B cell and modulate at least one biological function of the B cell.Type: GrantFiled: May 9, 2012Date of Patent: April 17, 2018Assignee: Biothera, Inc.Inventors: Nandita Bose, Anissa S. H. Chan, Michael E. Danielson, Mary A. Antonysamy, John P. Vasilakos, Keith B. Gorden, Steven M. Leonardo, William J. Grossman
-
Patent number: 9885726Abstract: This disclosure provides, in one aspect, a method for analyzing a sample from a subject for a biomarker that is indicative of the subject's immune response to ?-glucan. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti-?-glucan antibody compared to a reference standard, computing a Relative Antibody Unit (RAU) value for anti-?-glucan antibody in the sample, and identifying the subject as biomarker positive if the RAU value is greater than a predetermined RAU value for the biomarker anti-?-glucan antibody.Type: GrantFiled: December 1, 2014Date of Patent: February 6, 2018Assignee: Biothera, Inc.Inventors: Nandita Bose, Mary A. Antonysamy, Keith B. Gorden, Richard Walsh, Michael E. Danielson, Peter Maimonis
-
Publication number: 20160305955Abstract: This disclosure provides, in one aspect, a method for analyzing a sample from a subject for a biomarker that is indicative of the subject's immune response to ?-glucan. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti-?-glucan antibody compared to a reference standard, computing a Relative Antibody Unit (RAU) value for anti-?-glucan antibody in the sample, and identifying the subject as biomarker positive if the RAU value is greater than a predetermined RAU value for the biomarker anti-?-glucan antibody.Type: ApplicationFiled: December 1, 2014Publication date: October 20, 2016Inventors: Nandita Bose, Mary A. Antonysamy, Keith B. Gorden, Richard Walsh, Michael E. Danielson, Peter Maimonis
-
Patent number: 9145410Abstract: Pyrazolopyridin-4-amines, pyrazoloquinolin-4-amines, pyrazolonaphthyridin-4-amines, 6,7,8,9-tetrahydropyrazoloquinolin-4-amines, and prodrugs thereof, pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of use of these compounds as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.Type: GrantFiled: January 26, 2012Date of Patent: September 29, 2015Assignee: 3M Innovative Properties CompanyInventors: David S. Hays, Michael E. Danielson, John F. Gerster, Shri Niwas, Ryan B. Prince, Tushar A. Kshirsagar, Philip D. Heppner, William H. Moser, Joan T. Moseman, Matthew R. Radmer, Maureen A. Kavanagh, Sarah A. Strong, Jason D. Bonk
-
Publication number: 20150125461Abstract: This disclosure describes, in one aspect, a method for identifying ?-glucan binding to immune cells of a subject. Generally, the method includes obtaining a blood sample from the subject, the blood sample comprising immune cells, adding soluble ?-glucan to at least a portion of the blood sample and incubating the mixture under conditions allowing the soluble ?-glucan to bind to the immune cells, and detecting soluble ?-glucan bound to the immune cells. In another aspect, this disclosure describes a method that generally includes identifying the subject as a low binder of ?-glucan, and co-administering to the subject a soluble ?-glucan and an antibody preparation capable of converting the subject from a low binder to a high binder.Type: ApplicationFiled: March 14, 2013Publication date: May 7, 2015Applicant: Biothera, Inc.Inventors: William J. Grossman, Mary A. Antonysamy, Richard M. Walsh, Mariana I. Nelson, Nandita Bose, Michael E. Danielson, Kyle S. Michel
-
Publication number: 20150125451Abstract: This disclosure describes, in one aspect, a composition that includes a ?-glucan component and an antibody component that specifically binds to the ?-glucan. In another aspect, this disclosure describes a method of increasing a subject's response to ?-glucan immunotherapy. Generally, the method includes identifying the subject as a low binder of ?-glucan and administering to the subject a composition that comprises a ?-glucan moiety conjugated to the therapeutic antibody. In some cases, the therapeutic antibody can be an anti-tumor antibody.Type: ApplicationFiled: March 14, 2013Publication date: May 7, 2015Applicant: Biothera, Inc.Inventors: William J. Grossman, Mary A. Antonysamy, Richard M. Walsh, Mariana I. Nelson, Nandita Bose, Michael E. Danielson, Kyle S. Michel
-
Publication number: 20140370046Abstract: Described herein are beta-glucan compounds, compositions, and methods. Generally, the methods exploit the observation that beta-glucan compounds can bind to B cells. Thus, the methods generally include administering a beta-glucan compound to a subject in an amount effective for the beta-glucan compound to bind to a B cell and modulate at least one biological function of the B cell.Type: ApplicationFiled: May 9, 2012Publication date: December 18, 2014Applicant: Biothera, Inc.Inventors: Nandita Bose, Anissa S.H. Chan, Michael E. Danielson, Mary A. Antonysamy, John P. Vasilakos, Keith B. Gorden, Steven M. Leonardo, William J. Grossman
-
Patent number: 8846710Abstract: A method of preferentially inducing IFN-? biosynthesis in an animal comprising administering certain imidazo[4,5-c] ring compounds with a hydroxymethyl or hydroxyethyl substituent at the 2-position or pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of using these compounds a immunomodulators for treatment of diseases including viral and neoplastic diseases comprising preferentially inducing IFN-? biosynthesis in an animal are disclosed.Type: GrantFiled: February 22, 2006Date of Patent: September 30, 2014Assignee: 3M Innovative Properties CompanyInventors: Tushar A. Kshirsagar, Bryon A. Merrill, Scott E. Langer, Kyle J. Lindstrom, Sarah C. Slania, Gregory J. Marszalek, Joshua R. Wurst, Karl J. Manske, Shri Niwas, Gregory D. Lundquist, Jr., Philip D. Heppner, George W. Griesgraber, Michael E. Danielson
-
Patent number: 8835157Abstract: Methods of providing at least one reagent for use in a device for processing sample material, delivering at least one reagent to a device for processing sample material, and adding at least one reagent to at least one of the steps in a process for detecting or assaying a nucleic acid; a support film coated with a dry reagent layer; and a device for processing sample material having a support film coated with a dry reagent layer contained within at least one chamber of the device are disclosed.Type: GrantFiled: April 25, 2008Date of Patent: September 16, 2014Assignee: 3M Innovative Properties CompanyInventors: Ranjani V. Parthasarathy, Michael E. Danielson, John C. Faletti, William Bedingham
-
Patent number: 8546383Abstract: Fused [1,2]imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a —CH(—X1—R1)— group in the fused ring at the 1-position of the imidazo ring, pharmaceutical compositions containing the compounds, intermediates, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.Type: GrantFiled: May 25, 2012Date of Patent: October 1, 2013Assignee: 3M Innovative Properties CompanyInventors: George W. Griesgraber, Tushar A. Kshirsagar, Azim A. Celebi, Sarah J. Slania, Michael E. Danielson, Michael J. Rice, Joshua R. Wurst
-
Patent number: 8350034Abstract: Substituted fused [1,2]imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a —CH(—R1)— group in the fused ring at the 1-position of the imidazo ring, wherein R1 includes a functional group, for example, an amide, sulfonamide, urea, carbamate, ester, ketone, ether, a thio analog of the forgoing, sulfone, oxime, or hydroxylamine, pharmaceutical compositions containing the compounds, intermediates, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.Type: GrantFiled: August 2, 2011Date of Patent: January 8, 2013Assignee: 3M Innovative Properties CompanyInventors: George W. Griesgraber, Tushar A. Kshirsagar, Sarah J. Slania, Michael E. Danielson
-
Publication number: 20120232057Abstract: Fused [1,2]imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a —CH(—X1—R1)— group in the fused ring at the 1-position of the imidazo ring, pharmaceutical compositions containing the compounds, intermediates, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.Type: ApplicationFiled: May 25, 2012Publication date: September 13, 2012Inventors: George W. GRIESGRABER, Tushar A. KSHIRSAGAR, Azim A. CELEBI, Sarah J. SLANIA, Michael E. DANIELSON, Michael J. RICE, Joshua R. WURST